As many of you know, Noah drank a lot of wine and after the
As many of you know, Noah drank a lot of wine and after the floods had a lot of influence. He convinced the rich and powerful to choose wine as the leisure drug of choice and promoted its medicinal benefits. Cannabis was put on the shelf so to speak.
My main gripe with Noah is over his failure to protect many of the African grazing species that perished when he allowed the Lions and Tigers free reign. The unicorn became extinct during the third week.
Much of my information comes from my great...........................great uncle Pat who was chained to an oar in the bow of Noah's Ark.
2
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
iCapital Enhances Portfolio Construction Tools for Investors iCapital, a leading global fintech platform, has introduced significant enhancements to its innovative portfolio construction tool, iCapital Architect. This advanced platform is designed to simplify the integration of alternative investments into traditional portfolio strategies. Financial advisors gain access...
Continue Reading
Understanding Recent Market Movements The market experienced a turbulent session recently, sending investors into a state of caution. This volatility was significantly influenced by renewed discussions around tariffs impacting trade relationships, particularly involving technology and manufacturing sectors. The Impact of Tariffs on the Market Former President Trump's...
Continue Reading
Performance Systems Integration Merger with Summit Fire & Security Performance Systems Integration (PSI), recognized as the leading fire and life safety solutions provider in the Pacific Northwest, has completed a merger with Summit Fire & Security LLC, which is a subsidiary of SFP Holding, Inc. This merger marks a significant collaboration that aims to enhance the safety...
Continue Reading
Revealing Interim Results from Candel Therapeutics NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company dedicated to advancing biological immunotherapies to combat cancer, has announced noteworthy interim data stemming from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) targeting recurrent glioblastoma. This...
Continue Reading
Supernus Pharmaceuticals Hits Record Stock Levels Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has achieved a remarkable milestone, as its stock recently surged to a 52-week high of $35.45. This significant increase showcases the company’s strong financial performance and growth prospects, creating a wave of optimism among investors. The stock has risen an impressive...
Continue Reading
